[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"indolent-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:indolent-lymphoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,68,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100638914","pomalidomide-plus-anti-cd20-antibody-and-prednisone-in-frontline-indolent-b-cell-lymphoma-100638914",false,"NCT07609446","Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma","Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma: A Prospective, Multicenter, Phase II Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of sex;\n2. Confirmed diagnosis of follicular lymphoma (FL), or histopathologically confirmed CD20-positive marginal zone lymphoma (MZL), including extranodal marginal zone lymphoma (MALT), splenic marginal zone lymphoma (SMZL), and nodal marginal zone lymphoma (NMZL),or confirmed diagnosis of indolent mantle cell lymphoma (MCL);\n3. Patients with a confirmed diagnosis of chronic lymphocytic leukemia (CLL)\u002Fsmall lymphocytic lymphoma (SLL);\n4. Confirmed diagnosis of lymphoplasmacytic lymphoma\u002FWaldenstrom macroglobulinemia;\n5. Presence of indications for treatment of indolent B-cell lymphoma;\n6. No prior systemic antitumor therapy for lymphoma;\n7. ECOG-PS score 0-2;\n8. Essentially normal bone marrow hematopoietic function, with routine blood tests as follows: white blood cell count \\>3000\u002FuL, absolute neutrophil count ≥1.5 × 10\\^9\u002FL (use of granulocyte colony-stimulating factor is allowed), platelet count ≥75 × 10\\^9\u002FL (transfusion to reach this minimum platelet count is allowed), and hemoglobin ≥9.0 g\u002FdL (prior red blood cell transfusion or use of recombinant human erythropoietin is allowed). If peripheral blood abnormalities are caused by lymphoma involvement of the bone marrow or spleen, neutrophils≥1.0 × 10\\^9\u002FL and platelets≥50 × 10\\^9\u002FL are acceptable (the investigator may determine at his\u002Fher discretion whether enrollment is appropriate);\n9. Normal function of major organs:\n\n   1. Hepatic function: serum bilirubin ≤2.0 × ULN; serum ALT and AST ≤2.5 × ULN;\n   2. Renal function: creatinine clearance \\>30 mL\u002Fmin;\n10. Expected survival≥3 months as judged by the investigator; Voluntary written informed consent signed before trial screening;\n\nExclusion Criteria:\n\n1. Current or prior other malignancy, unless curative treatment has been performed and there has been no evidence of recurrence or metastasis within the past 5 years;\n2. Lymphoma involvement of the central nervous system or transformation to a higher-grade lymphoma;\n3. Hepatic or renal dysfunction unrelated to lymphoma: alanine aminotransferase (ALT) \\>3 times the upper limit of normal, aspartate aminotransferase (AST) \\>3 times the upper limit of normal, total bilirubin (TBIL) \\>2 times the upper limit of normal, or serum creatinine \\>1.5 times the upper limit of normal;\n4. Other serious medical conditions that would affect this study (e.g., uncontrolled diabetes, gastric ulcer, or other serious cardiopulmonary diseases). The investigator has the authority to make this determination;\n5. Severe or uncontrolled infection;\n6. Clinically manifest central nervous system dysfunction;\n7. Major surgery within the past 30 days (excluding lymph node biopsy);\n8. Pregnant or lactating women, or women of childbearing potential who have not used contraceptive measures;\n9. Allergy to the study drug; Patients considered unsuitable for enrollment by the investigator.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","12 Months","OBSERVATIONAL","A Phase II Study of Pomalidomide Combined with Anti-CD20 Monoclonal Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma Objective: This prospective, single-arm, Phase II trial aims to evaluate the efficacy and safety of first-line pomalidomide plus anti-CD20 antibody and prednisone in patients with indolent B-cell lymphoma.\n\nStudy Population: Approximately 30 adult patients (age ≥18 years) will be enrolled. Eligible histologies include follicular lymphoma (FL), CD20-positive marginal zone lymphoma (MZL: extranodal MALT, splenic SMZL, nodal NMZL), indolent mantle cell lymphoma (MCL), chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL), and lymphoplasmacytic lymphoma\u002FWaldenström macroglobulinemia. Patients must be treatment-naïve, have an indication for systemic therapy, ECOG performance status 0-2, and adequate bone marrow reserve (ANC ≥1.5×10⁹\u002FL, platelets ≥75×10⁹\u002FL, hemoglobin ≥9.0 g\u002FdL; lower thresholds permitted if marrow\u002Fspleen involvement, per investigator discretion). Adequate organ function is required: bilirubin ≤2×ULN, ALT\u002FAST ≤2.5×ULN, and creatinine clearance \\>30 mL\u002Fmin. Life expectancy must be ≥3 months, and written informed consent is mandatory.\n\nExclusion Criteria: Patients are excluded if they have another malignancy within 5 years (unless curatively treated without recurrence), CNS lymphoma involvement, transformation to high-grade lymphoma, uncontrolled infection, severe comorbidities affecting study participation, significant non-lymphoma-related organ dysfunction (ALT\u002FAST \\>3×ULN, bilirubin \\>2×ULN, creatinine \\>1.5×ULN), active CNS dysfunction, major surgery within 30 days, pregnancy or lactation, lack of contraception in women of childbearing potential, known drug hypersensitivity, or any condition deemed unsuitable by the investigator.\n\nTreatment Regimen: Induction consists of six 28-day cycles. Anti-CD20 antibody is administered at 375 mg\u002Fm² weekly during Cycle 1 and on Day 1 of Cycles 2-6. Pomalidomide is given at 4 mg\u002Fday on Days 2-22 of Cycles 1-6. Prednisone is administered at 100 mg\u002Fday on Days 1-5 of Cycles 1-6. Maintenance therapy continues for 2 years with pomalidomide 4 mg\u002Fday on Days 1-14 and anti-CD20 antibody 375 mg\u002Fm² on Day 1 every 8 weeks.\n\nEndpoints: The primary endpoint is overall response rate (ORR). Secondary endpoints include complete response rate (CR), progression-free survival (PFS), overall survival (OS), and safety (hematologic and non-hematologic adverse events).\n\nStatistical Methods: Continuous variables will be summarized with descriptive statistics; categorical variables with frequencies and percentages. Time-to-event endpoints (PFS, OS, and duration of response) will be analyzed using the Kaplan-Meier method, reporting medians, quartiles, and 90% confidence intervals, along with event and censoring counts. ORR will be tested statistically and reported with a 90% confidence interval.\n\nTimeline: The study is expected to begin in January 2026, complete enrollment by December 2026, and conclude by December 2027. The total planned sample size is 30 patients.",[25,26,27,28],"Indolent Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","Indolent Mantle Cell Lymphoma","NOT_YET_RECRUITING","2026-05-21",{"date":32,"type":33},"2026-05-27","ACTUAL",{"date":35,"type":20},"2026-05-01",{"date":37,"type":20},"2027-12-31",{"name":39,"class":40},"The First Affiliated Hospital of Soochow University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100628282","phase-2-efficacy-and-safety-of-lisaftoclax-apg-2575-monotherapy-in-patients-with-indolent-lymphoma-100628282","NCT07459608","Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of signing the informed consent form (ICF).\n2. Histologically confirmed diagnosis of an indolent lymphoma (CLL\u002FWM\u002FMZL), meeting one of the following conditions:\n\n   Cohort A: Previously untreated and ineligible for Bruton's Tyrosine Kinase inhibitor (BTKi) therapy due to severe comorbidities (e.g., uncontrolled hypertension, cardiac disease, or active infection, etc.).\n\n   Cohort B: Received only one prior line of BTKi as first-line treatment, did not achieve a partial response (PR), and discontinued BTKi due to intolerable treatment-related adverse events (e.g., atrial fibrillation, hemorrhage, infection, rash, etc.).\n3. Adequate bone marrow function, defined as:\n\n   1. Hemoglobin (Hb) ≥ 70 g\u002FL (without transfusion support within 7 days prior to the first dose of study drug).\n   2. Absolute neutrophil count (ANC) ≥ 0.5 × 10⁹\u002FL (independent of growth factor support within 7 days prior to the first dose of study drug).\n   3. Platelet count ≥ 50 × 10⁹\u002FL (without transfusion support within 7 days prior to the first dose of the study drug. If the patient has documented bone marrow involvement, a platelet count ≥ 30 × 10⁹\u002FL is acceptable, provided the investigator ensures adequate supportive care).\n4. Adequate hepatic and renal function, defined as:\n\n   1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN).\n   2. Creatinine clearance (Ccr) ≥ 40 ml\u002Fmin (estimated by the Cockcroft-Gault formula).\n   3. Total bilirubin \\\u003C 1.5 × ULN.\n5. Left ventricular ejection fraction (LVEF) ≥ the lower limit of normal (LLN, 50%).\n6. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 3.\n7. Life expectancy ≥ 3 months.\n8. Men, women of childbearing potential (WOCBP, defined as premenopausal women capable of becoming pregnant), and their partners must agree to use highly effective contraception methods (e.g., condoms, implants\u002Finjections\u002Foral contraceptives, intrauterine devices \\[IUD\\], abstinence, or a sterilized partner) during the treatment period and for 90 days after the last dose of the study drug. Postmenopausal women (at least 12 months of spontaneous amenorrhea) or surgically sterile women are not considered WOCBP.\n9. No other active malignant disease within the past 3 years, except for currently treated basal cell\n\nExclusion Criteria:\n\n1. Prior treatment with any B-cell lymphoma 2 (BCL-2) inhibitor.\n2. Patients with active infection (including active hepatitis B virus \\[HBV\\] or hepatitis C virus \\[HCV\\] infection, or human immunodeficiency virus \\[HIV\\] positivity) or any other serious uncontrolled medical condition (Patients who are hepatitis B surface antigen (HBsAg) positive or hepatitis B core antibody (HBcAb) seropositive are eligible if their HBV DNA is below the lower limit of detection\u002Fquantification and they are willing to undergo monthly HBV reactivation monitoring. Patients who are HCV antibody positive are eligible if their HCV RNA is below the lower limit of detection\u002Fquantification).\n3. Presence of other concurrent malignancies (except for those specified in the inclusion criteria) that may affect the interpretation of study results or treatment with the investigational drug, or patients with severe coagulation disorders, or severe impairment of cardiac, cerebral, pulmonary, hepatic, or renal function.\n4. History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 12 months prior to the first dose of the study drug.\n5. Administration of any live vaccine within 28 days prior to the first dose of the study drug.\n6. Women of childbearing potential (WOCBP) or men with partners of childbearing potential who are unwilling to use highly effective contraception; pregnant or breastfeeding women.\n7. Inability to swallow tablets, or presence of malabsorption syndrome, any disease significantly affecting gastrointestinal function, gastrectomy\u002Fsmall bowel resection, symptomatic inflammatory bowel disease or ulcerative colitis, or partial\u002Fcomplete bowel obstruction.\n8. Known hypersensitivity to the active pharmaceutical ingredient, excipients of the study drug, or its analogs.\n9. Requirement for concomitant treatment with strong inhibitors or inducers of cytochrome P450 (CYP) 3A.\n10. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's judgment, could compromise the patient's safety or pose an undue risk for study participation.",{"count":49,"type":20},75,"INTERVENTIONAL",[52],"PHASE2","This is a multicenter, prospective, single-arm phase II study designed to evaluate the safety and efficacy of lisaftoclax (APG-2575), an oral selective BCL-2 inhibitor, in patients with indolent B-cell lymphomas. The study will enroll adult patients with chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), or marginal zone lymphoma (MZL) who are either treatment-naïve but considered ineligible for Bruton tyrosine kinase (BTK) inhibitor therapy due to significant comorbidities, or who are intolerant to prior BTK inhibitor treatment.\n\nEligible patients will receive oral lisaftoclax once daily with a dose ramp-up to a target dose of 600 mg in 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or completion of the planned treatment period. The primary objective is to evaluate the safety and tolerability of lisaftoclax monotherapy, while secondary objectives include assessment of antitumor activity, including overall response rate (ORR), complete response (CR) rate, minimal residual disease (MRD) negativity, progression-free survival (PFS), duration of response (DOR), and overall survival (OS). Quality of life will also be assessed using the EORTC QLQ-C30 questionnaire.",[25,55,56,57],"WM","MZL","CLL \u002F SLL","2026-03-11",{"date":60,"type":33},"2026-03-13",{"date":62,"type":20},"2026-03-10",{"date":64,"type":20},"2028-03-01",{"name":66,"class":67},"Henan Cancer Hospital","OTHER_GOV",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":50,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100626924","phase-1-pomalidomide-combined-with-obinutuzumab-in-the-treatment-of-patients-with-relapsedrefractory-indolent-lymphoma-100626924","NCT07441954","Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed\u002FRefractory Indolent Lymphoma","A Prospective, Multicenter, Phase I\u002FII Clinical Study of Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed\u002FRefractory Indolent Lymphoma.","GP-1","Inclusion Criteria:\n\n1. Age ≥18 years old, regardless of gender;\n2. Histopathologically confirmed CD20+ indolent lymphoma (FL, MZL, or SLL), WHO grade 1-3a;.\n3. Relapsed or refractory disease after at least one prior line of therapy;.\n4. ECOG-PS 0-2;\n5. At least one measurable lesion;\n6. Bone marrow hematopoietic function is basically normal. Complete blood count: white blood cell count \\>3000\u002FuL, absolute neutrophil count ≥1.5×10\\^9\u002FL (use of granulocyte colony-stimulating factor is permitted), platelet count ≥75×10\\^9\u002FL (transfusion is allowed to achieve this minimum platelet count), hemoglobin ≥9.0g\u002FdL (prior red blood cell transfusion or use of recombinant human erythropoietin is permitted). If abnormal peripheral blood indices are caused by lymphoma infiltration of bone marrow or spleen, the investigator may exercise discretion in determining eligibility for enrollment.\n7. Normal function of major organs: Liver function: serum bilirubin ≤2.0×ULN, serum ALT and AST ≤2.5×ULN; Renal function: creatinine clearance \\>30mL\u002Fmin;.\n8. The investigator judged that the expected survival period was ≥3 months;\n9. The patient was fully informed and signed the informed consent form;.\n10. Female subjects must use effective contraception, not be pregnant, and agree to practice contraception during the trial and after the study ends. Male subjects must agree to practice contraception during the trial and for 30 days after the last treatment.\n\nExclusion Criteria:\n\n1. Any other type of lymphoma, including Burkitt lymphoma;\n2. The investigator confirms that the patient may progress to aggressive lymphoma.\n3. Patients with contraindications or allergies to the investigational drug.\n4. History of VTE or cerebral infarction prior to treatment;.\n5. Patients who have undergone major surgery within 30 days prior to enrollment that may significantly impair physical condition or increase the risk of thrombosis, or who have scheduled surgery during the study period. Subjects planning to undergo minor surgical procedures under local anesthesia that do not significantly affect physical condition or markedly increase thrombosis risk may participate in the study.\n6. Patients with uncontrolled or severe cardiovascular diseases, including myocardial infarction within 3 months prior to enrollment, unstable coronary artery disease, uncontrolled chronic congestive heart failure, Class III-IV heart failure as defined by the New York Heart Association (NYHA), or clinically significant pericardial disease;.\n7. Uncontrolled hypertension.\n8. Uncontrolled diabetes.\n9. Uncontrolled active infection, or acute active infection, requiring systemic use of antibiotics, antiviral or antifungal medications within two weeks prior to the first dose.\n10. HIV-positive.\n11. Active hepatitis B or C.\n12. History of other malignancies within 3 years prior to the first study drug administration.\n13. Any clinically significant medical condition or disorder that the investigator considers may affect compliance with the experimental protocol or the subject's ability to provide informed consent.\n14. The subject is a pregnant or lactating female.\n15. Patients with severe physical or mental illnesses that may interfere with participation in this clinical study as determined by the protocol or investigator's judgment; or conditions such as drug abuse, medical, psychological, or social circumstances that may affect the subject's participation or evaluation of study results.\n16. Patients currently receiving other investigational drug treatments.\n17. Participants who have taken part in other clinical trials within one month.\n18. Any other patients deemed ineligible for inclusion by the investigator.",{"count":77,"type":20},53,[79,52],"PHASE1","To explore the maximum tolerated dose (MTD) of pomalidomide in combination with obinutuzumab in patients with relapsed\u002Frefractory indolent lymphomas (including follicular lymphoma, marginal zone lymphoma, and chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma) treated with the pomalidomide plus obinutuzumab combination regimen, and to determine the recommended phase II dose (RP2D); concurrently evaluating the efficacy and safety of pomalidomide combined with obinutuzumab in patients with relapsed\u002Frefractory indolent lymphomas.",[25],"2026-02-26",{"date":84,"type":33},"2026-03-02",{"date":86,"type":20},"2026-03-20",{"date":88,"type":20},"2029-12-31",{"name":90,"class":40},"Institute of Hematology & Blood Diseases Hospital, China",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":50,"phases":98,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":41},"100591880","phase-2-a-phase-2-study-to-evaluate-the-safety-and-efficacy-of-pacritinib-in-relapsed-or-refractory-waldenstrm-macroglobulinemia-100591880","NCT06986174","A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia","Inclusion Criteria:\n\n* Age ≥18 years\n* ECOG performance status ≤2\n* Clinicopathological diagnosis of Waldenström Macroglobulinemia\n* Symptomatic disease meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenström macroglobulinemia. At least one of the following:\n\n  * constitutional symptoms: recurrent fever, night sweats, fatigue or weight loss\n  * progressive or symptomatic lymphadenopathy or splenomegaly\n  * hemoglobin ≤10 g\u002FdL\n  * platelet count ≤100 k\u002FuL\n  * hyperviscosity syndrome\n  * symptomatic peripheral neuropathy\n  * systemic amyloidosis\n  * renal insufficiency\n  * symptomatic cryoglobulinemia\n* Serum IgM level ≥ 2 times the upper limit of normal\n* Participants must meet the following organ and marrow functions as defined below:\n\n  * absolute neutrophil count ≥0.5 k\u002FuL without growth factor within 7 days\n  * platelet count ≥50 k\u002FuL without platelet transfusion within 7 days\n  * total bilirubin ≤1.5 times the upper limit of normal or ≤3 times the upper limit of normal with documented liver involvement, hemolysis or Gilbert's disease\n  * AST (SGOT) and ALT (SGPT) ≤2.5 times the upper limit of normal or ≤5 times the upper limit of normal with documented liver involvement\n  * Creatinine clearance ≥30 ml\u002Fmin using Cockcroft\u002FGault equation\n* Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged)\n* At least 2 prior lines of treatment for Waldenström Macroglobulinemia. Participants must either be BTK inhibitor exposed or not be a candidate for BTK therapy.\n* Women of childbearing potential: Females of childbearing potential (FCBP) will be required to use two highly effective forms of contraception simultaneously or will remain abstinent from heterosexual intercourse during the following periods related to this study:\n\n  1. while participating in the study; and 2) for at least three months (90 days) after discontinuation from the study. FCBP must be referred to a qualified provider of contraceptive methods if needed.\n\nExclusion Criteria:\n\n* Current history of uncontrolled HIV\n* Patients with a known history of HIV must have a viral load assessed for eligibility and must be on a stable antiretroviral regimen that can be administered concurrent with pacritinib.\n* Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below\n\n  * Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (antiHBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before enrollment. Patients who are hepatitis B PCR positive will be excluded.\n  * Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before enrollment. Patients who are hepatitis C RNA positive will be excluded.\n* Participants with chronic liver disease and hepatic impairment meeting Child-Pugh class B or C (Appendix B)\n* Participants who are pregnant, breast feeding, or planning to become pregnant while enrolled in this study or within 3 month after last study dose (2 weeks for breastfeeding)\n* Current CNS involvement by WM\n* Active alcohol or drug abuse\n* Concurrent administration of medications that are moderate or strong inhibitors or inducers of CYP3A within 14 days or 5 half-lives, whichever is shorter, prior to first dose of study drug.\n* Concurrent participation in another therapeutic clinical trial\n* History of another malignancy, except adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, localized prostate cancer, or other adequately treated cancer currently in complete remission\n* Prior or ongoing clinically significant illness, including active infections requiring antibiotics, of medical condition that, in the investigator's opinion, could affect the safety of the patient; alter the absorption, distribution, metabolism or excretion of the study drug; or impair the assessment of study results\n* Inability to swallow pills\n* Significant cardiovascular disease defined as:\n\n  * Unstable angina, or\n  * History of myocardial infarction within 6 months prior to planned start\n  * Previously documented left ventricular ejection fraction (LVEF) by any method of ≤ 45% in the 12 months prior to planned start; assessment of LVEF via echocardiogram or multigated acquisition (MUGA) scan during screening should be performed in selected patients as medically indicated, or\n  * Any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or\n  * Uncontrolled or symptomatic arrhythmias\n* Prolonged QT Interval with baseline QTc \\>480 msec using the Bazette formula\n* Ongoing, active infection.\n* Active bleeding requiring blood transfusion or other medical intervention. Participants requiring anticoagulation therapy are not excluded.",{"count":19,"type":20},[52],"This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM).\n\nThe name of the study drug involved in this study is:\n\n-Pacritinib (a type of kinase inhibitor)",[101,102,103,25],"Waldenström Macroglobulinemia","Lymphoplasmacytic Lymphoma","B-Cell Lymphoproliferative Disorder",[101,102,105,103,25],"Lymphoma","RECRUITING","2025-12-01",{"date":109,"type":33},"2025-12-05",{"date":111,"type":33},"2025-11-21",{"date":113,"type":20},"2032-10-01",{"name":115,"class":40},"Shayna Sarosiek, MD"]